K-mRNA Consortium support group to gain momentum

in vaccine development

Participation in Dong-A ST & E-Cell and increased synergy related to the consortium's division of roles in the entire cycle

A vaccine exclusively for the delta mutation virus is also being developed separately, including the selection of candidate substances

The research and development move of the K-mRNA Consortium formed to develop the next-generation COVID-19 vaccine is expected to gain further momentum.

 

The consortium consisting of Hanmi, ST Pharm, GC Pharma and KIMCo announced on the 9th that Dong-A ST, a major pharmaceutical company in the development and production of specialized drugs in Korea, and E-Cell, a company specializing in bio-original materials, participated in the consortium.

 

Since the launch of the consortium in June, the progress of the project has accelerated, and material companies and others seem to be joining as partners.

 

Dong-A ST is one of the representative pharmaceutical R&D companies in the domestic pharmaceutical bio industry, and will actively support the consortium's future application for approval of mRNA vaccines, clinical development, and licensing based on its rich experience and capabilities.

 

E-Cell is Korea's first leading bio-materials, parts, and equipment company that developed disposable bio-processing equipment and consumables such as disposable cell culture devices and disposable mixer bags.

 

At the time of launch, the consortium, which announced that it would expand additional participation from raw and subsidiary materials companies, universities, and research institutes, plans to open the door to companies that can play a role in the rapid implementation of the successful model of the entire cycle.

 

Currently, the consortium is developing the COVID-19 mRNA vaccine candidate STP2104 with the aim of entering phase 1 clinical trial within the year and commercializing it following conditional permission in the first half of next year.

 

The consortium is managing its schedule without a hitch, such as regularly sharing information and consulting with the MFDS every month for rapid clinical implementation.

 

In addition, it is preparing to establish a production system of 100 million doses of mRNA vaccine, which is the national vaccination volume, by the end of 2022.

 

In addition, a separate COVID-19 vaccine is being developed to respond to the delta mutation virus.

 

In this regard, ST Pharm, which is in charge of the consortium's clinical part, is conducting a preclinical efficacy evaluation after selecting an additional mRNA vaccine candidate, STP2130.